Trial Profile
Protective Mechanisms Against a Pandemic Respiratory Virus: B-cell, T-cell, and General Immune Response to Seasonal Influenza Vaccine. Year 4, 2012
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 26 Apr 2017
Price :
$35
*
At a glance
- Drugs Influenza virus vaccine (Primary) ; Influenza virus vaccine live (Primary)
- Indications Influenza virus infections
- Focus Pharmacodynamics
- Acronyms SLVP018
- 20 Jan 2017 New trial record